These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 38183209)

  • 1. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
    Shirouchi Y; Maruyama D
    Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific T-cell engagers for treatment of multiple myeloma.
    Ravi G; Costa LJ
    Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
    Moreau P; Touzeau C
    Blood; 2022 Jun; 139(26):3681-3687. PubMed ID: 35404996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
    Hosny M; Verkleij CPM; van der Schans J; Frerichs KA; Mutis T; Zweegman S; van de Donk NWCJ
    J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement.
    Heerma van Voss MR; Molenaar RJ; Korst CLBM; Bartelink IH; Baglio SR; Kruyswijk S; de Ruijter M; Zweegman S; Kuipers MT; van de Donk NWCJ
    Expert Opin Biol Ther; 2024 Sep; 24(9):889-901. PubMed ID: 39185748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma.
    Tacchetti P; Barbato S; Mancuso K; Zamagni E; Cavo M
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
    van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
    Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions.
    O'Neill C; van de Donk NWCJ
    EJHaem; 2023 Aug; 4(3):811-822. PubMed ID: 37601851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
    Wang X; Zhao A; Zhu J; Niu T
    Front Immunol; 2024; 15():1348955. PubMed ID: 38482019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibodies for the Treatment of Multiple Myeloma.
    Goldsmith SR; Streeter S; Covut F
    Curr Hematol Malig Rep; 2022 Dec; 17(6):286-297. PubMed ID: 36029366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
    Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
    Front Immunol; 2020; 11():762. PubMed ID: 32457743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma.
    Braun A; Gouni S; Pulles A; Strati P; Minnema MC; Budde LE
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433516. PubMed ID: 38935881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.